The biotech firm announced a $237 million Series E round, headed by Bristol Myers Squibb, to accelerate its agentic AI drug‑development platform and expand its oncology pipeline.
Pathos AI announced a $237 million Series E financing round, spearheaded by pharmaceutical giant Bristol Myers Squibb, to scale its agentic AI platform for drug discovery and broaden its oncology pipeline.
Series E Funding Highlights
The round brings together strategic investors and existing backers, with Bristol Myers Squibb taking the lead as the primary anchor. The capital will be deployed to enhance Pathos AI’s proprietary AI models, increase computational capacity, and accelerate pre‑clinical studies of novel cancer therapeutics.
Agentic AI Platform
Pathos AI’s platform combines large‑language models with reinforcement learning to autonomously generate, prioritize, and optimize drug candidates. By integrating biological data, molecular simulations, and clinical insights, the system aims to shorten the discovery timeline from years to months.
Oncology Pipeline Expansion
The new funding will support the advancement of several oncology programs, including targeted therapies for solid tumors and immuno‑oncology candidates. Pathos AI plans to move multiple lead compounds into IND‑enabling studies within the next 12‑18 months.
- Accelerate AI model training and validation
- Scale high‑performance computing infrastructure
- Advance pre‑clinical oncology candidates
- Deepen collaboration with Bristol Myers Squibb
The partnership with Bristol Myers Squibb not only provides financial backing but also offers access to extensive clinical data and regulatory expertise, which could streamline the transition of AI‑designed molecules into human trials.
For readers interested in broader AI developments in biotech, explore the AI category on uxc.news for related coverage.
Comments
No comments yet.